Table 2.
Clinical patient characteristic by cohort.
| Characteristics |
Training cohort of WCSUH-SCU (n = 50) |
Validation cohort of WCSUH-SCU (n = 50) |
Validation cohort of HNPPH (n = 42) |
p-value |
|---|---|---|---|---|
| Age at surgery (years), median (IQRs) |
50 (46–59.5) | 50 (44.5–57.5) | 50 (41.5–56) | 0.283 |
| Preoperative CA-125 (U/mL), median (IQRs) |
913.3 (396.4–2193.6) |
1346.4 (405.8–3093.6) |
482.5 (402.0–713.6) |
0.611 |
| Postoperative CA-125 (%) | ||||
| ≤ 35 U/mL | 25 (50) | 28 (56) | 23 (55) | 0.831 |
| >35 U/mL | 25 (50) | 22 (44) | 19 (45) | |
| FIGO stage (%) | ||||
| III | 43 (86) | 41 (82) | 28 (67) | 0.070 |
| IV | 7 (14) | 9 (18) | 14 (33) | |
| Residual (%) | ||||
| = 0 | 12 (24) | 14 (28) | 8 (19) | 0.584 |
| >0 | 38 (76) | 36 (72) | 34 (81) | |
| Tumor side (%) | ||||
| Unilateral | 23 (46) | 20 (40) | 23 (55) | 0.377 |
| Bilateral | 27 (54) | 30 (60) | 19 (45) | |
| Menopause status (%) | ||||
| Menopause | 37 (74) | 33 (66) | 31 (74) | 0.640 |
| Premenopausal | 13 (26) | 17 (34) | 11 (26) | |
| Recurrence (%) | ||||
| Yes | 20 (40) | 29 (58) | 32 (76) | 0.002 |
| No | 30 (60) | 21 (42) | 10 (24) | |
| Follow-up in censored patients (month), median (IQRs) |
46.1 (42.9–55.7) | 33.6 (31.4–35.2) | 25.6 (21.0–32.4) | – |
| Follow-up in recurrence (month), median (IQRs) |
26.6 (18.7–29.2) | 16.5 (12.6–20.0) | 16.4 (9.7–28.1) | – |
p-values are the result of Fisher exact tests (categorical variables) or F-tests (continuous variables). WCSUH-SCU, West China Second University Hospital of Sichuan University; HNPPH, Henan Provincial People's Hospital; CA-125, Carbohydrate Antigen 125; FIGO, International Federation of Gynecology and Obstetrics; IQRs, interquartile ranges.